ProMIS Neurosciences (PMN) Stock Price, News & Analysis

Company Overview

ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.

Key Stats

• Today's Range: $0.96 to $0.99
• 50-Day Range: $0.95 to $1.38
• 52-Week Range: $0.91 to $3.10
• Volume: 4,686 shs
• Average Volume: 70,893 shs
• Market Capitalization: $31.38 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ProMIS Neurosciences Stock Analysis - MarketRank™

ProMIS Neurosciences scored higher than 22% of companies evaluated by MarketBeat, and ranked 864th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for ProMIS Neurosciences.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ProMIS Neurosciences are expected to grow in the coming year, from ($0.24) to ($0.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ProMIS Neurosciences is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ProMIS Neurosciences is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ProMIS Neurosciences has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.16% of the float of ProMIS Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

ProMIS Neurosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProMIS Neurosciences has recently increased by 74.02%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ProMIS Neurosciences does not currently pay a dividend.

Dividend Growth

ProMIS Neurosciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.16% of the float of ProMIS Neurosciences has been sold short.

Short Interest Ratio / Days to Cover

ProMIS Neurosciences has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in ProMIS Neurosciences has recently increased by 74.02%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.25

News Sentiment

ProMIS Neurosciences has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for ProMIS Neurosciences this week, compared to 0 articles on an average week.

Search Interest

5 people have searched for PMN on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, ProMIS Neurosciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $164,600.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

Only 4.40% of the stock of ProMIS Neurosciences is held by insiders.

Percentage Held by Institutions

50.13% of the stock of ProMIS Neurosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PMN Stock Analysis - Frequently Asked Questions

How have PMN shares performed this year?

ProMIS Neurosciences' stock was trading at $1.15 at the beginning of 2024. Since then, PMN stock has decreased by 16.3% and is now trading at $0.9622.
View the best growth stocks for 2024 here.

How were ProMIS Neurosciences' earnings last quarter?

ProMIS Neurosciences, Inc. (NASDAQ:PMN) issued its earnings results on Thursday, August, 8th. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.01.

Who are ProMIS Neurosciences' major shareholders?

ProMIS Neurosciences' top institutional investors include Great Point Partners LLC (9.34%), Sphera Funds Management LTD. (6.45%) and Ally Bridge Group NY LLC (5.33%). Insiders that own company stock include Madge K Shafmaster and Patrick D Kirwin.
View institutional ownership trends.

How do I buy shares of ProMIS Neurosciences?

Shares of PMN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of ProMIS Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ProMIS Neurosciences investors own include Palantir Technologies (PLTR), PayPal (PYPL), Recursion Pharmaceuticals (RXRX), Pacific Biosciences of California (PACB), Editas Medicine (EDIT), Exscientia (EXAI) and Trimble (TRMB).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PMN
• CUSIP: N/A
• CIK: 1374339
• Web: www.promisneurosciences.com
• Phone: (416) 847-6898
• Fax: N/A
• Employees: 6
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-13,210,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -636.20%
• Return on Assets: -130.32%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.30
• Quick Ratio: 9.30

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 3,145.43
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.22 per share
• Price / Book: 4.37

Miscellaneous

• Outstanding Shares: 32,690,000
• Free Float: 31,251,000
• Market Cap: $31.45 million
• Optionable: Not Optionable
• Beta: 0.60